Comparative Pharmacokinetics Study of the Leutragin Peptide Drug in Blood Serum and Lung Tissue in C57BL/6Y Mice after Single Inhalation Administration-Reference-Cited by-同舟云学术

Comparative Pharmacokinetics Study of the Leutragin Peptide Drug in Blood Serum and Lung Tissue in C57BL/6Y Mice after Single Inhalation Administration

Published:2024-04-05 Issue:1 Volume:20 Page:21-32
ISSN:2713-0428
Container-title:Journal Biomed
language:
Short-container-title:BIOMEDICINE

Author:

Ogneva N. S.¹,Nesterov M. S.¹,Khvostov D. V.¹,Fokin Yu. V.¹,Karkischenko V. N.¹

Affiliation:

1. Scientific Center of Biomedical Technologies of the Federal Medical and Biological Agency of Russia

Abstract

This paper presents a study into the pharmacokinetics of a new inhaled anti-inflammatory hexapeptide, registered as “Leutragin”. This drug is used as a new treatment approach for viral pneumonias, whose severe course is directly related to the cytokine inflammatory cascade referred to as a cytokine storm. The study involved investigation of lung tissue and serum after a single inhalation administration of Leutragin to mice of the C57BL/6Y line at a dose of 150 mg/kg. The time required to reach the maximum concentration (Tmax) of Leutragin in serum and lung was 30 min and 10 min, respectively. The maximum concentration (Cmax) in lung was 358.5 ng/g, which exceeded the concentration maximum for blood (53.84 ng/g) by over six times. It was found that, after inhalation administration, Leutragin is rather rapidly eliminated from the body with the half-life of the drug (t1/2el) from blood serum and lungs ranging from 25.8 to 38.9 min.

Publisher

Scientific Center for Biomedical Technologies of the Federal Medical-Biological Agency

Reference17 articles.

1. Bebyakova N.A., Levitsky S.N., Komandresova T.M., Shabalina I.А. K mehanismam antikonstriktornogo effekta dalargina [To the mechanisms of the anticonstrictor effect of dalargin]. Arctic Evironmental Research. 2012. (In Russian).

2. Bebyakova N.A., Levitsky S.N., Khromova A.V., Shabalina I.А., Komandresova Т.М. Kardiovaskulyarnie effekty dalargina v usloviyah ostrogo stressa [Cardio-vascular effects of dalargin in conditions of acute stress]. Mezgdunarodniy nauchno-issledovatel’skiy jurnal [International Research Journal]. 2014;(8(27)Ч. 1):34–36 (In Russian).

3. Borovskaya T.Ph., Kurpas E.H., Gorislavec S.N. Opit ispol’zovaniya dalargina v lechenii bol’nih vnebol’nichnoy pnevmoniyey [Experience of using dalargin in the treatment of patients with out-of-hospital pneumonia]. Bulleten’ phiziologii i patologii dihaniya [Bulletin of physiology and pathology of respiration]. 2004;17:85–88. (In Russian).

4. Val’dman A.V. Pharmacology of neuropeptides. Sb. trudov [Collection of works]. Moscow, 1982:147. (In Russian).

5. Vinogradov V.A., Polonskiy V.M. Dalargin — perviy analog enkephalinov, primenyaemih v gastroenterologii [Dalargin — the first enkephalin analog, used in gastroenterology]. Ter. Arhiv. 1988;8:147–153 (In Russian).